Johnson & Johnson Total Assets increased by 0.8% to $200.89B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.7%, from $193.67B to $200.89B. Over 5 years (FY 2020 to FY 2025), Total Assets shows an upward trend with a 2.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Growth generally indicates business expansion, while a decline may suggest asset liquidation or a contraction in business scale.
This is the sum of all current and non-current assets owned by the company, representing the total resource base availab...
Universal financial metric used by all public companies to define the size of the balance sheet.
total_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $176.44B | $179.23B | $182.02B | $178.36B | $177.72B | $175.12B | $187.38B | $195.97B | $191.69B | $166.06B | $167.56B | $171.97B | $181.09B | $178.29B | $180.10B | $193.67B | $193.39B | $192.82B | $199.21B | $200.89B |
| QoQ Change | — | +1.6% | +1.6% | -2.0% | -0.4% | -1.5% | +7.0% | +4.6% | -2.2% | -13.4% | +0.9% | +2.6% | +5.3% | -1.5% | +1.0% | +7.5% | -0.1% | -0.3% | +3.3% | +0.8% |
| YoY Change | — | — | — | — | +0.7% | -2.3% | +2.9% | +9.9% | +7.9% | -5.2% | -10.6% | -12.2% | -5.5% | +7.4% | +7.5% | +12.6% | +6.8% | +8.1% | +10.6% | +3.7% |
| Segment | Q4 '22 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| MEDTECH | $70.96B | $74.71B | $84.32B | $85.11B | $86.75B | $86.50B | $86.48B | $86.18B |
| Innovative Medicine | — | $58.32B | $57.07B | $58.73B | $75.49B | $74.42B | $78.06B | $78.12B |
| General Corporate | $30.75B | $34.52B | — | $49.83B | $31.16B | $31.89B | $34.67B | $36.60B |
| Total | $187.38B | $167.56B | $180.10B | $193.67B | $193.39B | $192.82B | $199.21B | $200.89B |